Marksans Pharma Ltd Quarterly Results
Q3 FY25-26 Results Summary
Revenue
The revenue stands at ₹754.43 crore, reflecting a quarter-on-quarter *(QoQ) increase of 4.72 per cent from ₹720.41 crore. This corresponds to a year-on-year *(YoY) growth of 10.64 per cent.
Operating Profit
Operating Profit stands at ₹160.74 crore, reflecting a quarter-on-quarter *(QoQ) increase of 11.25 per cent from ₹144.49 crore. This corresponds to a year-on-year *(YoY) growth of 15.83 per cent.
PBDT
PBDT stands at ₹174.96 crore, reflecting a quarter-on-quarter *(QoQ) increase of 9.17 per cent from ₹160.26 crore. This corresponds to a year-on-year *(YoY) growth of 6.72 per cent.
Profit Before Tax
Profit Before Tax stands at ₹150.63 crore, reflecting a quarter-on-quarter *(QoQ) increase of 12.97 per cent from ₹133.34 crore. This corresponds to a year-on-year *(YoY) growth of 5.15 per cent.
Net Profit
Net Profit stands at ₹113.69 crore, reflecting a quarter-on-quarter *(QoQ) increase of 14.68 per cent from ₹99.14 crore. This represents a 8.21 per cent year-on-year *(YoY) growth for the same year.
- YoY compares a quarter to the same period last year, and QoQ compares it to the previous quarter.
Marksans Pharma Ltd Earnings
- YOY
- QOQ
Marksans Pharma Ltd Earning Charts
Revenue from Operations
in ₹ cr
EBITDA
in ₹ cr
Profit before Tax
in ₹ cr
Net Profit
in ₹ cr
Marksans Pharma Ltd Research Reports
| Action | Target Price (₹) | Broker | Date | Reports |
|---|---|---|---|---|
| Data Not Found | ||||
Marksans Pharma Ltd Financial Reports
Marksans Pharma Ltd Stock Prices Compare with Peers
| Company | 1 Day | 1 Week | 1 month | 3 month | 6 month | 1 Year |
|---|---|---|---|---|---|---|
| Marksans Pharma | 15.27% | 17.18% | 32.56% | 46.40% | 33.46% | 0.99% |
| Alembic Pharma | -0.54% | 0.86% | -0.64% | 6.69% | -16.16% | -23.62% |
| Alivus Life | 3.48% | 2.95% | 4.32% | 19.44% | 21.05% | 0.82% |
| Concord Biotech | 0.45% | 2.05% | 7.66% | -6.81% | -20.27% | -25.69% |
| Viyash Scientific | -1.85% | 1.88% | 23.01% | 20.79% | 13.45% | 31.08% |
| Strides Pharma | -1.60% | 1.79% | 5.92% | 36.60% | 30.71% | 63.13% |
| Sanofi Consumer | 0.09% | -3.89% | -0.16% | 3.47% | -2.30% | -8.66% |
Company Info
Company Information
Chairman & Managing Director : Mark Saldanha
Company Sec. & Compli. Officer : Harshavardhan Panigrahi
Whole-time Director : Sandra Saldanha
Independent Director : Digant Mahesh Parikh
Whole-time Director : Varddhman Vikramaditya Jain
Independent Director : Abhinna Sundar Mohanty
Non Executive Director : Sunny Sharma
Independent Director : Shailaja Vardhan
Independent Director : Srinivas Mishra